Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. on September 22, 2021. The report discloses the execution of change in control severance agreements with three key officers: David Kirn (CEO), August Moretti (CFO), and Robert Stephen Fishman (CMO). The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol FDMT.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements triggered by specific employment termination scenarios.
Material Changes
The primary material change disclosed is the establishment of new severance terms for the CEO, CFO, and CMO effective September 22, 2021. These agreements define compensation entitlements in the event of termination without "cause" or resignation for "good reason," with enhanced benefits applicable during a "change in control" period.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or general management commentary regarding business operations. It details specific contractual terms for severance:
- Standard Termination:
- CEO: 12 months base salary, pro-rated bonus, prior year earned bonus, and 12 months COBRA.
- CFO/CMO: 9 months base salary, pro-rated bonus, prior year earned bonus, and 9 months COBRA.
- Change in Control Termination:
- CEO: 18 months base salary, 12 months plus pro-rated bonus, prior year earned bonus, 18 months COBRA, and full equity vesting acceleration (excluding performance awards).
- CFO/CMO: 12 months base salary, 12 months plus pro-rated bonus, prior year earned bonus, 12 months COBRA, and full equity vesting acceleration (excluding performance awards).
- Conditions: Eligibility requires the timely delivery of an effective release of claims and compliance with restrictive covenants.
Investor Verification Checklist
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for complete definitions of "cause," "good reason," and "change in control."
- Verify the current base salary and target bonus amounts for the CEO, CFO, and CMO to calculate potential severance liabilities.
- Assess the impact of full equity vesting acceleration on the company's share count and dilution in a change in control scenario.
- Confirm whether any performance-vesting awards are subject to different acceleration terms as noted in the agreements.